Molecular and clinical aspects of connective tissue
1988; Wiley; Volume: 18; Issue: 2 Linguagem: Inglês
10.1111/j.1365-2362.1988.tb02400.x
ISSN1365-2362
AutoresTh. Krieg, R. Hein, Atsushi Hatamochi, Monique Aumailley,
Tópico(s)Skin and Cellular Biology Research
ResumoEuropean Journal of Clinical InvestigationVolume 18, Issue 2 p. 105-123 Molecular and clinical aspects of connective tissue Prof. Dr TH. KRIEG, Corresponding Author Prof. Dr TH. KRIEG Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenDermatologische Klinik der LMU, Frauenlobstr. 9–11, D-8000 München 2, FRG.Search for more papers by this authorR. HEIN, R. HEIN Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenSearch for more papers by this authorA. HATAMOCHI, A. HATAMOCHI Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenSearch for more papers by this authorM. AUMAILLEY, M. AUMAILLEY Max-Planck-Institut für BiochemieSearch for more papers by this author Prof. Dr TH. KRIEG, Corresponding Author Prof. Dr TH. KRIEG Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenDermatologische Klinik der LMU, Frauenlobstr. 9–11, D-8000 München 2, FRG.Search for more papers by this authorR. HEIN, R. HEIN Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenSearch for more papers by this authorA. HATAMOCHI, A. HATAMOCHI Dermatologische Klinik und Poliklinik der Ludwig-Maximilians-Universität MünchenSearch for more papers by this authorM. AUMAILLEY, M. AUMAILLEY Max-Planck-Institut für BiochemieSearch for more papers by this author First published: February 1988 https://doi.org/10.1111/j.1365-2362.1988.tb02400.xCitations: 42AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Hay ED. Cell Biology of the Extracellular Matrix. New York: Plenum Press, 1983. 2 K Kühn, T Krieg, eds. Connective Tissue: Biological and Clinical Aspects. Basel: Karger Verlag, 1986. 3 Humphries MJ, Yamada KM. Non-collageous glycoproteins. Rheumatology 1986; 10: 104– 42. 4 Timpl R, Dziadek M. Structure, development and molecular pathology of basement membranes. Int Rev Exp Pathol 1986; 29: 1– 112. 5 Martin GR, Timpl R, Müller PK, Kühn K. The genetically distinct collagens. Trends Biochem Sci 1985; 10: 285– 7. 6 Burgeson R, Morris NP. The collagen family of proteins. In: J Uitto, AJ Perejda, eds. Connective Tissue Disease. New York: Marcel Dekker Inc., 1987: 3– 28. 7 Fietzek PP, Kühn K. The primary structure of collagen. Int Rev Connect Tissue Res 1975; 7: 1– 10. 8 Fessler JH, Fessler LI. Biosynthesis of collagen. Ann Rev Biochem 1978; 47: 129– 62. 9 Miller EJ, Matukas VG. Chick cartilage collagen: a new type of α1 chain not present in bone or skin of the species. Proc Natl Acad Sci USA 1969; 64: 1264– 8. 10 Miller EJ, Epstein EJ, Piez KA. Identification of three genetically distinct collagens by cyanogen bromide cleavage of insoluble human skin and cartilage collagen. Biochem Biophys Res Commun 1971; 42: 1024– 9. 11 Henkel W, Glanville RW. Covalent crosslinking between molecules of type I and type III collagen. The involvement of the N-terminal, nonhelical regions of the α1 (I) and α1 (III) chains in the formation of intermolecular crosslinks. Eur J Biochem 1982; 122: 205– 13. 12 Kühn K. The collagen family — variations in the molecular and supramolecular structure. Rheumatology 1986; 10: 29– 69. 13 Yaoita H, Foidart JM, Katz SI. Localization of the collageneous components in skin basement membrane. J Invest Dermatol 1978; 70: 191– 3. 14 Timpl R, Wiedemann H, v Delden V, Furthmayr H, Kühn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem 1981; 120: 203– 11. 15 Burgeson RW, Adli FA, Kaitila II, Hollister DW. Fetal membrane collagens: identification of two new collagen α-chains. Proc Natl Acad Sci USA 1976; 73: 2579– 83. 16 Chung E, Rhodes RK, Miller EJ. Isolation of three collageneous components of probable basement membrane origin from several tissues. Biochem Biophys Res Commun 1976; 71: 1167– 74. 17 Burgeson RE, Hollister DW. Collagen heterogeneity in human cartilage: identification of several new collagen chains. Biochem Biophys Res Commun 1979; 87: 1124– 31. 18 Jander R, Rauterberg J, Voss B, Bassewitz DB von. A cysteinerich collagenous protein from bovine placenta. Isolation of its constituent polypeptide chains and some properties of the non-denatured protein. Eur J Biochem 1981; 114: 17– 25. 19 Hessle H, Engvall E. Type VI collagen — studies on its localization, structure, and biosynthetic form with monoclonal antibodies. J Biol Chem 1984; 259: 3955– 61. 20 Bruns RR. Beaded filaments and long-spacing fibrils: relation to type VI collagen. J Ultrastruct Res 1984; 89: 136– 45. 21 v.d. Mark H, Aumailley M, Wick G, Fleischmajer R, Timpl R. Immunochemistry, genuine size and tissue localization of collagen VI. Eur J Biochem 1984; 142: 493– 502. 22 Bentz H, Morris NP, Murray LW, Sakai LY, Hollister SW, Burgeson RW. Isolation and partial characterization of a new human collagen with extended triple-helical structural domain. Proc Natl Acad Sci USA 1983; 80: 3168– 72. 23 Sakai LY, Keene DR, Morris NP, Burgeson RE. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 1986; 103: 1577– 86. 24 Sage H, Trueb B, Bornstein P. Biosynthesis and structural properties of endothelial cell type VIII collagen. J Biol Chem 1983; 258: 13391– 401. 25 Lozano G, Ninomiya Y, Thompson H, Olsen BR. A novel class of vertebrate collagen genes: chicken type IX collagen. Proc Natl Acad Sci USA 1985; 82: 4050– 4. 26 Bruckner P, Vaughan L, Winterhalter KH. Type IX collagen from sternal cartilage of chicken embryo contains covalently bound glycosaminoglycans. Proc Natl Acad Sci USA 1985; 82: 2608– 612. 27 Schmidt TM, Conrad HE. A unique low molecular weight collagen secreted by cultured chick embryo chondrocytes. J Biol chem 1982; 257: 12444– 50. 28 Kühn K. Structural and functional domains of collagen: a comparison of the protein with its gene. Coll Relat Res 1984; 4: 309– 22. 29 Kivirikko KJ, Myllylä R. Post-translational Modifications. Collagen in Health and Diseases. Edinburgh: Churchill Livingstone, 1982. 30 Fleischmajer R, Olsen BR, Timpl R, Perlish JS, Lovelace O. Collagen fibril formation during embryogenesis. Proc Natl Acad Sci USA 1983; 80: 3354– 8. 31 Fleischmajer R, Perlish JS. The role of the aminopropeptide in collagen fibrillogenesis. Rheumatology 1986; 10: 91– 103. 32 Werb Z. Degradation of collagen. In: J Weiss, ed. Collagen in Health and Disease. Edinburgh: Churchill Livingstone, 1982: 121– 34. 33 Harris ED, Krane SM. Collagenase. N Engl J Med 1974; 12: 857– 61. 34 Ruoslahti E, Engvall E, Hayman E. Fibronectin: current concepts of its structure and functions. Coll Relat Res 1981; 1: 95– 128. 35 Yamada K. Cell surface interactions with extracellular materials. Ann Rev Biochem 1983; 52: 761– 99. 36 Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517– 8. 37 Akiyama SK, Yamada K. Fibronectin. Adv Enzymol 1987; 59: 1– 57. 38 Barnes D, Silnutzer J. Isolation of human serum spreading factor. J Biol Chem 1983; 258: 12548– 52. 39 Hayman E, Pierschbacher M, Öhgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA 1983; 80: 4003– 7. 40 Suzuki S, Pierschbacher M, Ruoslahti E. Domain structure of vitronectin: alignment of active sites. J Biol Chem 1984; 259: 15307– 14. 41 Hewitt A, Varner H, Silver M, Dessau W, Wilkes L, Martin GR. The isolation and partial characterization of chondronectin, an attachment factor for chondrocytes. J Biol Chem 1982; 257: 2330– 4. 42 Timpl R, Rohde H, Robey P, Rennard S, Foidart J-M, Martin GR. Laminin — a glycoprotein from basement membranes. J Biol Chem 1979; 254: 9933– 7. 43 Aumailley M, Nurcombe V, Edgar D, Paulsson M, Timpl R. The cellular interactions of laminin fragments. Cell adhesion with two fragment-specific high affinity binding sites. J Biol Chem 1987; 262: 11532– 8. 44 Edgar D, Timpl R, Thoenen H. The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival. EMBO J 1984; 3: 1463– 8. 45 Laurie GW, Bing JT, Kleinman HK et al. Localization of binding sites for laminin, heparan sulfate proteoglycan and fibronectin on basement membrane (type IV) collagen. J Mol Biol 1986; 189: 205– 216. 46 Graf J, Iwamoto Y, Sasaki M et al. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis and receptor binding. Cell 1987; 48: 989– 96. 47 Terranova VP, Aumailley M, Sultan LH, Martin GR, Kleinmann HK. Regulation of cell attachment and cell number by fibronectin and laminin. J Cell Physiol 1986; 127: 473– 9. 48 Turpeenniemi-Hujanen T, Thorgeirsson UP, Rao CN, Liotta LA. Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem 1986; 261: 1883– 9. 49 Dziadek M, Paulsson M, Timpl R. Identification and interaction repertoire of large forms of the basement membrane protein nidogen. EMBO J 1985; 4: 2513– 8. 50 Carlin B, Jaffe R, Bender B, Chung AE. Entactin, a novel basal lamina associated sulfated glycoprotein. J Biol Chem 1981; 256: 5209– 214. 51 Uitto J. Biochemistry of the elastic fibers in normal connective tissues and its alterations in diseases. J Invest Dermatol 1979; 72: 1– 10. 52 Mecham RP. Elastin biosynthesis: a look at the current scene. Connect Tissue Res 1981; 8: 155– 60. 53 Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350 kd glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1987; 103: 2499– 509. 54 Hardingham T. Proteoglycans: their structure, interactions and molecular organization in cartilage. Biochem Soc Trans 1981; 9: 489– 97. 55 Sillence DD, Senn A, Danks MD. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 15: 101– 16. 56 Smith R, Francis MJD, Houghton GR. The Brittle Bone Syndrome: Osteogenesis Imperfecta. Butterworth, London, 1983. 57 Penttinen RP, Lichtenstein JR, Martin GR, McKusick VA. Abnormal collagen metabolism in cultured cells in osteogenesis imperfecta. Proc Natl Acad Sci USA 1975; 72: 586– 9. 58 Müller PK, Lemmen C, Gay S, Meigel WN. Disturbance in the regulation of the type of collagen synthesized in a form of osteogenesis imperfecta. Eur J Biochem 1975; 59: 97– 104. 59 Krieg T, Kirsch E, Müller PK. Osteogenesis imperfecta: biochemical and clinical evaluation of 17 cases. Klin Wochenschr 1981; 59: 91– 3. 60 Trelstad RL, Rubin D, Gross J. Osteogenesis imperfecta congenita; evidence for a generalized molecular disorder. Lab Invest 1977; 36: 501– 8. 61 Kirsch E, Krieg T, Remberger K, Fendel H, Bruckner P, Müller PK. Disorder of collagen metabolism in a patient with osteogenesis imperfecta (lethal type): increased degree of hydroxylation of lysine in collagen types I and III. Eur J Clin Invest 1981; 11: 39– 47. 62 Kirsch E, Glanville RW, Krieg T, Müller P. Analysis of cyanogen bromide peptides of type I collagen from a patient with lethal osteogenesis imperfecta. Biochem J 1983; 211: 599– 603. 63 Nicholls AC, Osse G, Schloon HG et al. The clinical features of homozygous α2 (I) chain collagen deficient osteogenesis imperfecta. J Med Genet 1984; 21: 257– 62. 64 Cole W, Chan D, Chambers G, Walker J, Bateman J. Deletion of 24 amino acids from the pro- α1 (I) chain of type I procollagen in a patient with the Ehlers-Danlos-syndrome type VII. J Biol Chem 1986; 261: 5496– 503. 65 Bateman JF, Chan D, Walker ID, Rogers JG, Cole WG. Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the α1 (I) chain of type I collagen. J Biol Chem 1987; 262: 7021– 7. 66 Chu M-L, Gargiulo V, Williams CJ, Ramirez F. Multiexon deletion in an osteogenesis imperfecta variant with increased type III collagen mRNA. J Biol Chem 1985; 260: 691– 4. 67 Chu ML, Williams, CJ, Pepe G, Hirsch JL, Prockop DJ, Ramirez F. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature 1983; 104: 78– 80. 68 Barsh GS, Roush CL, Bonadio J, Byers PH, Gelinas RE. Intronmediated recombination may cause a deletion in an α1 type I collagen chain in a lethal form of osteogenesis imperfecta. Proc Natl Acad Sci USA 1988; 82: 2870– 4. 69 Steinmann B, Rao VH, Vogel A, Bruckner P, Gitzelmann R, Byers PH. Cysteine in the triple-helical domain of one allelic product of the α1 (I) gene of type I collagen produces a lethal form of osteogenesis imperfecta. J Biol Chem 1984; 259: 11129– 38. 70 Cohn DH, Byers PH, Steinmann B, Gelinas RE. Lethal osteogenesis imperfecta resulting from a single nucleotide change in one human pro- α1 (I) collagen allele. Proc Natl Acad Sci USA 1986; 83: 6045– 7. 71 Nicholls AC, Pope FM, Craig P. An abnormal collagen α chain containing cysteine in autosomal dominant osteogenesis imperfecta. Br Med J 1984; 288: 112– 3. 72 Steinmann B, Tuderman L, Peltonen L, Martin GR, McKusick VA, Prockop DJ. Evidence for a structural mutation of procollagen type I in a patient with the Ehlers-Danlos syndrome type VII. J Biol Chem 1980; 255: 8887– 93. 73 Sippola M, Kaffe S, Prockop DJ. A heterozygous defect for structurally altered pro- α2 chain of type I procollagen in a mild variant of osteogenesis imperfecta. The altered structure decreases the thermal stability of pro-collagen and makes it resistant to procollagen N-proteinase. J Biol Chem 1984; 259: 14094– 100. 74 Byers PH, Shapiro JR, Rowe DW, David KE, Holbrook KA. Abnormal α2 chain in type I collagen from a patient with a form of osteogenesis imperfecta. J Clin Invest 1983; 71: 689– 97. 75 De Wet WJ, Sippola M, Tromp G, Prockop D, Chu M-L, Ramirez F. Use of R-loop mapping for the assessment of human collagen mutations. J Biol Chem 1986; 261: 3857– 62. 76 De Wet WJ, Pihlajaniemi I, Meyer J, Kelly TE, Prockop DJ. Synthesis of a shortened pro-α2 (I) chain and decreased synthesis of pro-α2 (I) chains in a proband with osteogenesis imperfecta. J Biol Chem 1983; 258: 7721– 8. 77 Bonadio J, Byers PH. Subtle structural alterations in the chains of type I procollagen produce osteogenesis imperfecta type II. Nature 1985; 316: 363– 6. 78 Pihlajaniemi T, Dickson LA, Pope FM et al. Osteogenesis imperfecta: cloning of a pro-α2 (I) collagen gene with a frameshift mutation. J Biol Chem 1984; 259: 12941– 4. 79 Bateman JF, Mascara T, Chan D, Cole WG. A structural mutation of the collagen α1 (I) CB7 peptide in lethal perinatal osteogenesis imperfecta. J Biol Chem 1987; 262: 4445– 1. 80 McKusick VA. Heritable Disorders of Connective Tissue. 5. Aufl. Mosby, St Louis, 1986. 81 Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med 1979; 300: 772– 7. 82 Krieg T, Müller PK. The Marfan's syndrome. Exp Cell Biol 1977; 45: 207– 21. 83 Byers PH, Siegel RC, Petersen KE, Rowe DW, Holbrook KA, Smith LT, Chang YH, Fu JCC. Marfan syndrome: abnormal α2 chain in type I collagen. Proc Natl Acad Sci USA 1981; 78: 7455– 9. 84 Abraham PA, Perejda AJ Carnes WH, Uitto J. Marfan syndrome: demonstration of abnormal elastin in aorta. J Clin Invest 1982; 70: 1245– 52. 85 Appel A, Horwitz AL, Dorfman A. Cell-free synthesis of hyaluronic acid in Marfan syndrome. J Biol Chem 1979; 254: 12199– 203. 86 McKusick VA. Mendelian Inheritance in Man. Johns Hopkins University Press, Baltimore, 1983. 87 Beighton P, Price A. Lord J, Dickson E. Variants of the Ehlers-Danlos syndrome. Clinical, biochemical, haematological and chromosomal features of 100 patients. Ann Rheum Dis 1969; 28: 228– 45. 88 Krieg T, Ihme A, Weber L, Kirsch E, Müller PK. Molecular defects of collagen metabolism in the Ehlers-Danlos syndome. Int J Dermatol 1981; 20: 415– 20. 89 Vogel A, Holbrook KA, Steinmann B, Gitzelmann R, Byers PH. Abnormal collagen fibril structure in the gravis form (type I) of Ehlers-Danlos syndrome. Lab Invest 1979; 40: 201– 6. 90 Holbrook KA, Byers PH. Structural abnormalities in the dermal collagen and elastic matrix from the skin of patients with inherited connective tissue disorders. J Invest Dermatol 1982; 79: 7– 16s. 91 Sack G. Status dysvascularis; ein Fall von besonderer Zereißlichkeit der Blutgefäße. Dtsch Arch Klin Med 1936; 176: 663– 9. 92 Barabas AP. Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical types and a hypothesis to explain the basis defect(s). Br Med J 1967; 2: 612– 3. 93 Byers PH, Holbrook KA, Barsh GS, Smith LT, Bornstein P. Altered secretion of type III collagen in a form of type IV Ehlers-Danlos syndrome: biochemical studies in cultured fibroblasts. Lab Invest 1977; 44: 336– 41. 94 Byers PH, Holbrook KA, McGillivray B, MacLeod PM, Lowry RB. Clinical and ultrastructural heterogeneity of type IV Ehlers-Danlos syndrome. Hum Genet 1979; 47: 141– 50. 95 Pope FM, Martin GR, Lichtenstein JR et al. Patient with Ehlers-Danlos syndrome type IV lack type III collagen. Proc Natl Acad Sci USA 1975; 72: 1314– 6. 96 Gay S, Martin GR, Müller PK, Timpl R, Kühn K. Simultaneous synthesis of types I and III collagen by fibroblasts in culture. Proc Natl Acad Sci USA 1976; 72: 4037– 40. 97 Aumailley M, Krieg T, Dessau W, Müller PK, Timpl R, Bricaud H. Biochemical and immunological studies of fibroblasts derived from a patient with Ehlers-Danlos syndrome type IV demonstrate reduced type III collagen synthesis. Arch Dermatol Res 1980; 269: 169– 77. 98 Aumailley M, Pöschl E, Martin GR, Yamada Y, Müller PK. Low production of procollagen III by skin fibroblasts from patients with Ehlers-Danlos syndrome type IV is not caused by decreased levels of procollagen III mRNA. Eur J Clin Invest 1988; 18: 207– 12. 99 Stolle CA, Pyeritz RE, Myers JC, Prockop DJ. Synthesis of an altered type III procollagen in a patient with type IV Ehlers-Danlos syndrome. A structural change in the α1 (III) chain which makes the protein more susceptible to proteinases. J Biol Chem 1985; 260: 1927– 44. 100 Di Ferrante N, Leachman RD, Angelini P et al. Lysyl oxidase deficiency in Ehlers-Danlos syndrome type V. Connect Tissue Res 1975; 3: 49– 53. 101 Siegel RC, Black CM, Bailey AJ. Crosslinking of collagen in the X-linked Ehlers-Danlos syndrome type V. Biochem Biophys Res Commun 1979; 88: 281– 7. 102 Pinnell SR, Krane SM, Kenzora JE, Glimcher MJ. A hereditable disorder of connective tissue. Hydroxylysine deficient collagen. N Engl J Med 1972; 289: 1013– 20. 103 Krane SM, Pinnell SR, Erbe RW. Lysyl-protocollagen hydroxylase deficiency in fibroblasts from siblings with hydroxylysine-deficient collagen. Proc Natl Acad Sci USA 1972; 69: 2899– 903. 104 Miller RL, Elsas LJ, Priest RE. Ascorbate action in normal and mutant lysyl hydroxylase from cultured dermal fibroblasts. J Invest Dermatol 1979; 72: 241– 7. 105 Elsas LJ, Miller RL, Pinnell SR. Inherited human collagen lysyl hydroxylase deficiency: ascorbic acid response. J Pediatr 1978; 92: 378– 84. 106 Eyre RD, Glimcher MJ. Reducible crosslinks in hydroxylysine-deficient collagens of a heritable disorder of connective tissue. Proc Natl Acad Sci USA 1972; 69: 2594– 8. 107 Ihme A, Risteli L, Krieg T, Risteli J, Kruse K, Müller PK. Biochemical characterization of variants of the Ehlers-Danlos syndrome type VI. Eur J Clin Invest 1983; 13: 357– 62. 108 Krieg T, Feldmann U, Kessler W, Müller PK. Biochemical characterization of Ehlers-Danlos syndrome type VI in a family with one affected infant. Hum Genet 1979; 46: 41– 9. 109 Steinmann B, Gitzelmann R, Vogel A, Grant ME, Harwood R. Ehlers-Danlos syndrome in two sibblings with deficient lysyl hydroxylase deficient skin. Helv Paediatr Acta 1975; 30: 255– 74. 110 Judish GF, Waziri M, Krachmer JH. Ocular Ehlers-Danlos syndrome with normal lysyl hydroxylase activity. Arch Ophthalmol 1976; 94: 1489– 91. 111 Lichtenstein JR, Martin GR, Kohn LD, Byers PH, McKusick VA. Defect in conversion of procollagen to collagen in a form of Ehlers-Danlos syndrome. Science 1973; 182: 298– 300. 112 Lapière CM, Lenaers A, Kohn LP. Procollagen peptidase: an enzyme excising the coordination peptides of procollagen. Proc Natl Acad Sci USA 1971; 68: 3054– 8. 113 Lenaers A, Ansay M, Nusgen B, Lapière CM. Collagen made of extended α chains, procollagen, in genetically-defective dermatosparactic calves. Eur J Biochem 1971; 23: 533– 9. 114 Steinmann B, Tuderman L, Peltonen L, Martin GR, McKusick VA, Prockop DJ. Evidence for a structural mutation of procollagen type I in a patient with Ehlers-Danlos syndrome type VII. J Biol Chem 1980; 255: 8887– 93. 115 Stewart RE, Hollister DW, Rimoin DL. A new variant of Ehlers-Danlos syndrome: an autosomal dominant disorder of fragile skin, abnormal scarring and generalized periodontosis. Birth Defects 1977; 38: 88– 93. 116 Linch DC, Aston DHC. Ehlers-Danlos syndrome presenting with juvenile destruction periodontitis. Br Dent J 1979; 147: 95– 7. 117 Nelson DL, King RA. Ehlers Danlos syndrome type VIII. J Am Acad Dermatol 1981; 5: 297– 303. 118 Sartoris DJ, Luzzati L, Weaver DD, MacFarlane JD, Hollister DW, Parker BR. Type IX Ehlers-Danlos syndrome. A new variant with pathognomonic radiographic features. Radiology 1984; 152: 665– 70. 119 Kuivaniemi H, Peltonen L, Palotie A, Kaitila I, Kivirikko KI. Abnormal copper metabolism and deficient lysyl oxidase activity in a heritable connective tissue disorder. J Clin Invest 1982; 69: 730– 6. 120 Kuivaniemi H, Peltonen L, Kivirikko KI. Type IX Ehlers-Danlos syndrome and Menkes' syndrome: the decrease in lysyl oxidase activity is associated with a corresponding deficiency in the enzyme protein. Am J Hum Genet 1985; 37: 798– 808. 121 Arneson MA, Hammerschmidt DE, Furcht LT, King RA. A new form of Ehlers-Danlos syndrome: fibronectin corrects defective platelet function. J Am Med Assoc 1980; 224: 144– 7. 122 Beighton, P. The dominant and recessive forms of cutis laxa. J Med Genet 1972; 9: 216– 21. 123 Mensing H, Krieg T, Meigel W, Braun-Falco O. Cutis laxa. Hautarzt 1984; 35: 506– 11. 124 Byers PH, Siegel RC, Holbrook KA, Narayanan AS, Bornstein P, Hall JG. X-linked cutis laxa: defective collagen cross-link formation due to decreased lysyl oxidase activity. N Engl J Med 1980; 303: 61– 5. 125 Hashimoto K, Kanzaki T. Cutis laxa. Ultrastructural and biochemical studies. Arch Dermatol Res 1975; 111: 861– 73. 126 Taieb A, Aumailley M, Courouge-Dorcier D et al. Collagen studies in congenital cutis laxa. Arch Dermatol Res 1987; 279: 308– 14. 127 Danks DM, Campbell PE, Stevens BJ, Mayne V, Cartwright E. Menkes' kinky-hair syndrome. An inherited defect in copper absorption with widespread effects. Pediatrics 1972; 80: 188– 201. 128 Kang AH, Trelstad RL. A collagen defect in homocystinuria. J Clin Invest 1973; 52: 2571– 8. 129 Briggaman RA, Wheeler CE. The epidermal—dermal junction. J Invest Dermatol 1975; 65: 71– 84. 130 Katz SI. The epidermal basement membrane zone — structure, ontogeny and role in diseases. J Am Acad Dermatol 1984; 11: 1025– 37. 131 Weber L, Krieg T, Timpl R, Basalmembranen — Struktur, Funktion, Pathologie. Hautarzt 1984; 35: 279– 86. 132 Briggaman RA. Biochemical composition of the epidermal—dermal junction and other basement membrane. J Invest Dermatol 1982; 88: 1– 6. 133 Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement—membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1983; 16: 1007– 13. 134 Schnyder UW. Hereditäre Epidermolysen. Klassifikation, Erbprognose und Therapie. In: O Braun-Falco, S Marghescu (Hrsg.) Fortschritte in der praktischen Dermatologie und Venerologie, Bd. 8. Heidelberg: Springer, 1976: 1– 8. 135 Krieg T, Schurig V, Braun-Falco O. Hereditäre bullöse Epidermolysen. Neuere Aspekte zur Diagnostik und Therapie. Hautarzt 1986; 37: 185– 9. 136 Briggaman RA, Wheeler CE. Epidermolysis bullosa dystrophica recessive: a possible role of anchoring fibrils in the pathogenesis. J Invest Dermatol 1975; 65: 203– 11. 137 Bauer EA. Recessive dystrophic epidermolysis bullosa: evidence for an altered collagenase in fibroblasts cultures. Proc Natl Acad Sci USA 1977; 74: 4646– 50. 138 Valle KJ, Bauer EA. Enhanced biosynthesis of human skin collagenase in fibroblasts culture from recessive dystrophic epidermolysis bullosa. J Clin Invest 1980; 66: 176– 87. 139 Mauch C, Krieg T. Pathogenesis of fibrosis — introduction and general aspects. Rheumatology 1986; 10: 372– 84. 140 Fleischmajer R. The pathophysiology of scleroderma. Int J Dermatol 1977; 16: 310– 8. 141 LeRoy EC. Scleroderma (systemic sclerosis). In: WB Kelley, S Ruffy, LB Sledge, eds. Textbook of Rheumatology. Saunders WB, 1981. 142 Gauss-Müller V, Kleinman HK, Martin GR, Schiffmann E. Role of attachment factors and attractants in fibroblast chemotaxis. J Lab Clin Med 1980; 96: 1071– 80. 143 Grotendorst G, Martin GR. Cell movement in wound-healing and fibrosis. Rheumatology 1986; 10: 385– 403. 144 Kang AH. Fibroblast activation. J Lab Clin Med 1978; 92: 1– 4. 145 Wahl SM, Wahl LM, McCarthy JB. Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol 1978; 121: 942– 6. 146 Johnson RL, Ziff M. Lymphokine stimulation of collagen accumulation. J Clin Invest 1976; 58: 240– 52. 147 Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18: 18– 21. 148 Kähari V, Vuorio T, Nänto-Salonen K, Vuorio E. Increased type I collagen mRNA levels in cultured scleroderma fibroblasts. Biochim Biophys Acta 1984; 181: 183– 6. 149 Kähari VM, Multimaki P, Vuorio E. Elevated pro-α2 (I) collagen messenger RNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding gene. FEBS Lett 1987; 215: 331– 4. 150 Fleischmajer R, Perlish JS, Krieg T, Timpl R. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol 1981; 75: 400– 3. 151 Botstein RG, Sherer GK, LeRoy EC. Fibroblast selection in scleroderma. Arthritis Rheum 1982; 25: 189– 95. 152 Poole AR. Changes in the collagen and proteoglycan of articular cartilage in arthritis. Rheumatology 1986; 10: 316– 71. 153 Uitto J, Bauer E, Eisen A. Scleroderma: increased biosynthesis of triple-helical type I and type III procollagen associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 1979; 64: 921– 80. 154 v.d. Mark K. Differentiation, modulation and dedifferentiation of chondrocytes. Rheumatology 1986; 10: 272– 315. 155 Gay S, Müller PK, Lemmen C, Remberger K, Matzen K, Kühn K. Immunohistological study on collagen in cartilage bone metamorphosis and degenerative osteoarthrosis. Klin Wschr 1976; 54: 969– 76. 156 Gay S, Kresina TF. Immunological disorders of collagen. In: JB Weiss, MIV Jayson, eds. Collagen in Health and Disease. Edinburgh: Churchill Livingstone, 1982: 269– 88. 157 Butkowski RJ, Langeveld JPM, Wieslander J, Hamilton J, Hudson BG. Localization of the goodpasture epitope to a novel chain of basement-membrane collagen. J Biol Chem 1987; 262: 7874– 7. 158 Woodley OT, Burgeson RE, Lunstrom GP et al. The epidermolysis bullosa acquisita antigen is type VII procollagen. Clin Res 1987; 35: 726 (abstr). 159 Foidart JM, Abe S, Martin GR et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978; 299: 1203– 7. 160 Towbin H, Rosenfelder G, Wieslander J et al. Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl (α1–3)-galactose epitopes. J Exp Med 1987; 166: 419– 32. 161 Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a basement membrane protein of stratified squamous epithelia. Cell 1981; 24: 887– 903. 162 Liotta LA, Rao CW, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636– 49. 163 Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283: 139– 46. 164 Yaminishi Y, Dabbous MK, Hashimoto K. Effect of collagenolytic activity in basal cell epithelioma of the skin on reconstituted collagen and physical properties and kinetics of the crude enzyme. Cancer Res 1972; 32: 2551– 60. 165 Burman JF, Carter RL. Lysis of type I collagen by squamous carcinomas of the head and neck. Int J Cancer 1985; 36: 109– 16. 166 Liotta LA, Abe S, Gehron-Robey P, Martin GR. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979; 76: 2268– 72. 167 Liotta LA, Tryggvason K, Garbisa S, Hat I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67– 8. 168 Barsky SH, Rao CW, Hyams D, Liotta LA. Characterization of a laminin receptor from human breast carcinoma tissue. Breast Cancer Res Treat 1984; 4: 181– 8. 169 Terranova VP, Rao CN, Kalebic T, Margulies JMK, Liotta LA. Laminin receptor on human breast carcinoma cells. Proc Natl Acad Sci USA 1983; 80: 444– 8. 170 Wewer UM, Liotta LA, Jaye M et al. Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. Proc Natl Acad Sci USA 1986; 83: 7137– 41. 171 Iwamoto Y, Robey FA, Graf J et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987; 238: 1132– 4. Citing Literature Volume18, Issue2February 1988Pages 105-123 ReferencesRelatedInformation
Referência(s)